Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688302.SS

STRONG SELLREMOVE

Hinova Pharmaceuticals Inc. · Healthcare · China · $582M · Avg Vol: $7M/d

14
StockRank
Q
38
V
37
M
26
P/E (TTM)
—
ROE
-12.3%
D/E
0.1x
Dividend %
—
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

Hinova Pharmaceuticals is a pre-revenue biopharmaceutical company. Its highly speculative drug pipeline carries binary clinical trial risks, failing our quality compounder criteria.

COMPANY DESCRIPTION

Hinova Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for oncology and metabolic diseases. The company's competitive moat is driven by its proprietary targeted protein degradation (PROTAC) and deuterated drug discovery platforms. It operates as an innovative biotechnology player with a pipeline of high-potential, small-molecule candidates targeting unmet clinical needs.

FINANCIAL SUMMARY

Year2022202320242025CAGR
Revenue243,981054,2163M131.5%
EPS-0.49-0.44-0.30-0.21—
Shares99M99M99M99M0.0%
Debt5M2M1M16M43.6%
Equity234M202M176M157M-12.5%
Op CF-47M-38M-28M-16M—
Inv CF-61M-15M-4M-21M—
Fin CF150M-5M-599,49714M—
Loading...
PRICE (1M)-24.0%
4.945.405.866.326.78Apr 30May 26Jun 15
SMA 50SMA 200
Close
$4.94
RSI (14)
17.9
52W High
$10.64
From 52W High
0.5%

SCORE BREAKDOWN

Quality
38
ROIC
-11.6%33.5
ROE
-12.3%34.0
GP/Assets
3.5%16.5
Op. Margin
-117.5%16.2
FCF/Assets
-4.1%37.5
Piotroski
—28.8
Int. Cover
-50.0x6.5
D/E Ratio
0.10x65.5
Current Ratio
7.04x80.1
Value
37
P/E (TTM)
—N/A
EV/EBITDA
-16.5x85.7
P/FCF
—N/A
P/B
3.2x37.4
P/S
71.0x8.8
Div Yield
—N/A
Momentum
26
52W High %
46%19.8
RS 6M
-37%32.6
SMA 50/200
0.88x27.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$582M
P/E (Forward)
—
Gross Margin
99.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688302.SS are excluded.

TickerCompanyMkt CapStockRankSignal
688302.SSHinova Pharmaceuticals Inc.(you)$582M14STRONG SELL
300149.SZChemPartner PharmaTech Co.,Ltd.$642M15STRONG SELL
2105.HKLaekna, Inc.$666M15STRONG SELL
300318.SZBeijing Bohui Innovation Biotechnology Group Co., Ltd.$613M12STRONG SELL
688136.SSKexing Biopharm Co., Ltd.$626M12STRONG SELL
1167.HKJacobio Pharmaceuticals Group Co., Ltd.$490M12STRONG SELL
2591.HKGuangzhou Innogen Pharmaceutical Group Co., Ltd$648M7STRONG SELL
688639.SSAnhui Huaheng Biotechnology Co., Ltd.$868M17STRONG SELL
2256.HKAbbisko Cayman Limited$826M18STRONG SELL
6996.HKAntengene Corporation Limited$347M15STRONG SELL

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.0%

Hinova Pharmaceuticals Inc. (688302.SS) — Stock Score Summary

Hinova Pharmaceuticals Inc. (688302.SS) has a MoatMap StockRank of 14/100 based on Quality (38/100), Value (37/100), and Momentum (26/100) factor scores. The current signal is STRONG SELL. Hinova Pharmaceuticals is a pre-revenue biopharmaceutical company. Its highly speculative drug pipeline carries binary clinical trial risks, failing our quality compounder criteria.

Hinova Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for oncology and metabolic diseases. The company's competitive moat is driven by its proprietary targeted protein degradation (PROTAC) and deuterated drug discovery platforms. It operates as an innovative biotechnology player with a pipeline of high-potential, small-molecule candidates targeting unmet clinical needs.

Key Financial Metrics

Price$4.94
Market Cap$582M
Price/Book3.19
Return on Equity-12.3%
Return on Invested Capital-11.6%
Debt/Equity10.16
Gross Margin99.3%
Operating Margin-117.5%
Free Cash Flow$-1M

Hinova Pharmaceuticals Inc. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Hinova Pharmaceuticals Inc.’s (688302.SS) StockRank?
MoatMap’s StockRank for Hinova Pharmaceuticals Inc. (688302.SS) is 14/100, with a Strong Sell signal. It is a composite of Quality (38), Value (37), and Momentum (26) factor ranks across MoatMap’s 19,000+ stock universe.
Does Hinova Pharmaceuticals Inc. have an economic moat?
Hinova Pharmaceuticals Inc. (688302.SS) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Hinova Pharmaceuticals Inc. a buy, hold, or sell?
MoatMap’s current signal for Hinova Pharmaceuticals Inc. (688302.SS) is Strong Sell, based on a StockRank of 14/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Hinova Pharmaceuticals Inc. in?
Hinova Pharmaceuticals Inc. (688302.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).
Browse all ranked stocks688302.SS deep dive reportAI ChampionsHow we score stocksSense-check another stock